As it reached over 250 metric tons in 2013, the Chinese albumin market has become the world’s largest in volume and in value. The current supply, whether domestic or imported, hardly meets the demand, which is expected to continue to grow in the next few years.

Volume replacement therapy to correct oncotic pressure and maintain adequate levels to carry various proteins and metal ions are two key indications for albumin usage in China. Its prescription for other conditions, such as kidney diseases, oncology, cirrhosis and others, including “comfort or nutritional siuations” will also contribute to the market expansion.

China’s continuing economic development and growth in healthcare spending will impact albumin demand in the future. At the same time, the pressure to increase efficiency in healthcare delivery may make alternatives to albumin attractive in certain treatment settings and for certain indications.

Using an extensive Chinese database as well as primary research to forecast usage trends, this report has the following objectives:

  • To describe the current use of albumin by disease condition in China, and
  • To develop an annual forecast of the albumin demand in China from 2013 to 2020 in grams and dollars.

A detailed proposal is available from the Marketing Research Bureau.